Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by longterm56on Sep 10, 2020 6:44pm

119 Views

Post# 31540032

RE:RE:RE:RE:Just how Massive is this News?

NO!!! Please don't say "more waiting". I was convinced that the "next announcement" would be the trigger ... I can't stand anymore waiting!!!

-LT

qwerty22 wrote:
<snip>

Today has been a huge revelation but in many ways I still think we are where we've been for a long time, waiting for the regulators to approve a Ph3 trial. When (if) that happens then the unusual way this program has come about will become less important and maybe the focus can shift to the value.

Wino115 wrote: Maybe. I'm not counting on much love there. I heard Leno at NatBkCan wrote and had a bunch of issues that he could have easily cleared up with a call to mgmt which he clearly must not have done. Questioned whether FDA will make them do more work on non-HIV to get that data prior to a trial, thinks they'll ask for more than the 650 proposed, etc... In other words, he thinks the last year of consultation they've been having was done without any input from regulators. My reading is that they were pushed in this direction specifically by the regulators and in doing so worked with them on what it should look like. In other words, there should be no surprises in their submission in a few weeks time and it will include everything the regulators wanted and told them they wanted in the back and forth over the last half a year. Leno's been a sleep at the wheel for a while now. He should be embarrased saying things like that in an actual research paper. Easy questions that could have been answered in a 15 minute phone call with management instead of publishing what appear to be incorrect facts.

1998novl wrote: Thanks Wino nice work here. I'm most interested on the response from the RBC Analyst. He asked some good questions today and seems very interested- maybe he'll change his tune towards patents and give NASH some kind of value?